United Services Automobile Association acquired a new position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 268,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,394,000. United Services Automobile Association owned about 0.38% of Sangamo Therapeutics as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of SGMO. Royce & Associates LP raised its stake in shares of Sangamo Therapeutics by 40.1% in the fourth quarter. Royce & Associates LP now owns 751,100 shares of the biopharmaceutical company’s stock worth $2,291,000 after buying an additional 215,000 shares during the period. Tocqueville Asset Management L.P. raised its stake in shares of Sangamo Therapeutics by 57.8% in the first quarter. Tocqueville Asset Management L.P. now owns 390,915 shares of the biopharmaceutical company’s stock worth $2,033,000 after buying an additional 143,250 shares during the period. Parametric Portfolio Associates LLC acquired a new stake in shares of Sangamo Therapeutics during the first quarter worth $578,000. Franklin Street Advisors Inc. NC acquired a new stake in shares of Sangamo Therapeutics during the first quarter worth $398,000. Finally, Candriam Luxembourg S.C.A. raised its stake in shares of Sangamo Therapeutics by 35.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 270,000 shares of the biopharmaceutical company’s stock worth $1,404,000 after buying an additional 70,000 shares during the period. Hedge funds and other institutional investors own 59.24% of the company’s stock.
Shares of Sangamo Therapeutics, Inc. (NASDAQ SGMO) traded down 0.52% during mid-day trading on Friday, hitting $9.50. The company had a trading volume of 1,263,868 shares. Sangamo Therapeutics, Inc. has a 12-month low of $2.65 and a 12-month high of $10.50. The firm’s market cap is $683.42 million. The firm’s 50 day moving average is $8.44 and its 200-day moving average is $5.60.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.03. Sangamo Therapeutics had a negative return on equity of 50.76% and a negative net margin of 380.44%. The company had revenue of $3.40 million for the quarter, compared to analyst estimates of $4.14 million. During the same period in the prior year, the company posted ($0.23) EPS. The company’s revenue was down 12.8% compared to the same quarter last year. On average, equities analysts expect that Sangamo Therapeutics, Inc. will post ($0.93) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “268,100 Shares in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Acquired by United Services Automobile Association” was originally reported by BNB Daily and is owned by of BNB Daily. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.baseball-news-blog.com/2017/07/22/united-services-automobile-association-acquires-new-position-in-sangamo-biosciences-inc-sgmo-updated-updated.html.
SGMO has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. ValuEngine raised Sangamo Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $17.00 target price on shares of Sangamo Therapeutics in a report on Thursday, June 22nd. Finally, Wedbush reaffirmed a “neutral” rating and set a $4.00 target price (down previously from $6.00) on shares of Sangamo Therapeutics in a report on Tuesday, May 16th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. Sangamo Therapeutics has a consensus rating of “Hold” and an average price target of $8.50.
In other news, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $10.00, for a total value of $150,000.00. Following the sale, the vice president now directly owns 35,517 shares in the company, valued at approximately $355,170. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 19,639 shares of company stock worth $184,765. Corporate insiders own 8.10% of the company’s stock.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.